P53 pathway in apoptosis induced by all-trans-retinoic acid in acute myeloblastic leukaemia cells

Acta Haematologica

Volumn 103, Issue 3, 2000, Pages 135-143

  Zheng, A ^a   Mantymaa, P ^a   Saily, M ^a   Savolainen, E R ^b   Vahakangas K ^a   Koistinen, P ^a,b  

^a Department of Internal Medicine ^*

^b UNIVERSITY OF OULU   (Finland)

Author keywords

Acute myeloblastic leukaemia; All frans retinoic acid; Apoptosis; Bax; Bcl 2; P53

Indexed keywords

BAX PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; RETINOIC ACID; TUMOR PROTEIN;

ACUTE DISEASE; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL CULTURE; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MYELOID LEUKEMIA; PATHOLOGY; PHYSIOLOGY; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ACUTE DISEASE; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, BCL-2; GENES, P53; HUMANS; LEUKEMIA, MYELOID; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRETINOIN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033642445     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000041036     Document Type: Article

References (42)

1. Searle J, Lawson TA, Abbot PJ, Harmon B, Kcrr JFR: An electron microscope study of the mode of cell death induced by cancerchcmotherapcutic agents in populations of proliferating normal and ncoplastic cells. J Pathol 1975;116:129-138.
2. Hickman JA: Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 1992;! 1:121-139.
3. Rudin CM, Thompson CB: Apoptosis and disease: Regulation and clinical relevance of programmed cell death. Annu Rev Med 1997;48:267-281.
4. Lowe SW, Rulcy HE, Jacks T, Houseman DE: p53 dependent apoptosis modulates the cytotoxicity of anticancer drugs. Cell 1993;74:957-968.
5. Reed JC: Bcl-2 family proteins: Regulators of apoptosis and chemoresistance in hematological malignancies. Semin Hcmatol 1997;34:9-19.
6. Hockcnberry DM, Oltvai ZN, Yin X-M, Millman CL, Korsmeycr SJ: Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell !993;75:241-251.
7. Oltvai ZN, Millman CL, Korsmeycr SJ: Bcl-2 hctcrodimcrizcs in vivo with a conserved homolog, Bax, that accelerates programmed cell death.Celll993;74:609-619.
8. MiyashitaT, Krajewski S, Krajcwska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-1805.
9. Selvakumaran M, Lin HK, Miyashita T, Wang HG, Krajewski S, Reed JC, Hoffman B, Liebermann D: Immediate early up-regulation of bax expression by p53 but not TGF beta-1: A paradigm for distinct apoptotic pathways. Oncogene 1994;9:1791-1798.
10. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of human bax gene. Cell 1995;80:293-299.
11. Wang YS, Szekely L, Okan I, Klein G, Wiman KG: Wild-type p53 triggered apoptosis is inhibited by bcl-2 in a v-Hijr-induced T-cell lymphoma line. Oncogene 1993;8:3427-3431.
12. Licbermann DA, Huffman B, Steinman RA: Molecular controls of growth arrest and apoptosis: p53-depcndcnt and independent pathways. Oncogene 1995;11:199-210.
13. Symonds H, Krall L, Remington L, SacnzRobies M, Lo\ve S, Jacks T, Van Dyke T: p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 1994;78:703-711.
14. Greenblatt MS, Bennet WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogcncsis. Cancer Res 1994;54:4855-4878.
15. Imamura J, Miyoshi I, Kocffler P: p53 in hématologie malignancies. Blood 1994;84:2412-2421.
16. Prcudhommc C, Fenaux P: The clinical significance of mutations of the p53 tumour suppressor gene in hacmatological malignancies. Br J Haematol 1997;98:502-511.
17. Schottelius A, Brennscheid TU, Ludwig W-D, Mertelsmann RH, Hcrrmann F, Lubbert M: Mechanisms of p53 alteration in acute leukemias. Leukemia 1994;8:1673-1681.
18. Lcvinc AJ: p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331.
19. Zhang W, Hu G, Estey E, Hester J, Deisseroth A: Altered conformation of the p53 protein in myeloid leukemia cells and mitogen-stimulated normal blood cells. Oncogcnc 1992;7:1645-1647.
20. Zhu Y-M, Bradbury D, Russell N: Expression of different conformations of p53 in the blast cells of acute mycloblastic leukaemia is related to in vitro growth characteristics. Br J Cancer 1993;68:85I-855.
21. Zheng A, Castrcn K, Säily M, Savolainen E-R, Koistinen P, Vähäkangas K: p53 status of newly established acute myeloid leukaemia cell lines. BrJ Cancer 1999;79:407-415.
22. Lotan R: Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochim Biophys Acta 1980;605:33-91.
23. Douer D, Koeffler P: Retinoic acid enhances colony-stimulating factor-induced clonal growth of normal human myeloid progenitor cells in vitro. ExpCell Res 1982;138:193-198.
24. Breitman TR, Selonick SE, Collins SJ: Induction of differentiation of the human promyclocytic leukemia cell line HL-60 by retinoic acid. Proc Natl Acad Sei USA 1980;77:2936-2940.
25. Breitman TR, Collins SJ, Kneene BR: Terminal differentiation of human promyclocytic cells in primary culture in response to retinoic acid. Blood 1981:57:1000-1004.
26. Martin SJ, Bradley JG, Cotter TG: HL-60 cells induced to differentiate towards ncutrophils subsequently die via apoptosis. Clin Exp Immunol 1990:9:448-453.
27. Douer D, Kocffler P: Retinoic acid: Inhibition of the clonal growth of human mycloid leukemia cells. J Clin Invest 1982;69:277-283.
28. Zheng A, Savolainen E-R, Koistincn P: Allfra/w-rctinoic acid induces apoptosis in acute myeloblastic leukaemia cells. Apoptosis 1997; 2:319-329.
29. Hu ZB, Minden MD, McCulloch EA: Direct evidence for the participation of bcl-2 in the regulation by retinoic acid of the Ara-C sensitivity of Icukemic stem cells. Leukemia 1995;9: 1667-1673.
30. Calabresse C, Barbey S, Venturini L, Balitrand N, Degos L, Pénaux P, Chomienne C: In vitro treatment with retinoids or the topoisomerase inhibitor, VP-16, evidences different functional apoptotic pathways in acute promyelocytic leukcmic cells. Leukemia 1995;9:2049-2057.
31. Bradbury DA, Aldington S, Zhu YM, Rüssel NH: Down-regulation of bcl-2 in AML blasts by all-/ra/tt-retinoic acid and its relationship to CD34 antigen expression. Br J Hacmatol 1996; 94:671-675.
32. Pisani F, Del Poeta G, Aronica G, Venditti A, Caravita T, Amadori S: In vitro down-regulation of bcl-2 expression by all-trans-retinoic acid in AML blasts. Ann Hematol 1997;75:145-147.
33. van Engeland M, Nicland LJW, Ramaekers FCS, Scutte B, Reutclingsperger PM: Annexin V affinity assay: A review on an apoptosis detection system based on phosphatidylscrinc exposure. Cytometry 1998;31:1-9.
34. Zheng A, Mäntymaa P, Säily M, Siitoncn T, Savolaincn E-R, Koistincn P: An association between mitochondrial function and all-trans-retinoic acid-induced apoptosis in acute mycloblastic leukaemia cells. Br J Hacmatol 1999;105:215-224.
35. Agarwal ML, Taylor WR, Chcrnov MV, Chernova OB, Stark GR: The p53 network. J Biol Cheml998;273:l-4.
36. Pritsche M, Haessler C, Brandner G: Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogenel993;8:307-318.
37. Lotem J, Sachs L: Control of apoptosis in hematopoicsis and leukemia by cytokincs, tumor suppressor and oncogenes. Leukemia 1996;10:925-931.
38. Yonisch-Rouach E, Resnitzky K, Lotem J, Sachs L, Kimchi A, Oren M: Wild type p53 induces apoptosis of myeloid leukemic cells that is inhibited by intcrleukin-6. Nature 1991;352:345-347.
39. White E: Life, death, and the pursuit of apoptosis. Genes Dev 1996;10:I-15.
40. Lotem J, Sachs L: Control of sensitivity to induction of apoptosis in myeloid leukemic cells by differentiation and bcl-2 dependent and independent pathways. Cell Growth Differ 1994;5:321-327.
41. Peled A, Zipori D, Rotter V: Cooperation between p53-dcpcndcnt and p53-indcpendent apoptotic pathways in myeloid cells. Cancer Rcsl996;56:2148-2156.
42. Malcomson RDG, Oren M, Wyllie AH, Harrison DJ: p53-independent death and p53-induced protection against apoptosis in fibroblasts treated with chemothcrapeutic drugs. Br J Cancer 1995;72:952-957.